Chronic, recurrent Lymphocytic Leukemia Not Yet Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04230304Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyTreatment